Moderna succeeds in mRNA flu shot after phase 3 trials; seeking approval

Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.

Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.

“Our mRNA platform is working. With today’s positive Phase 3 flu results, along with previous results in COVID and RSV, we are now three for three on advancing respiratory disease programs to positive Phase 3 data,”

Stéphane Bancel, Chief Executive Officer of Moderna

Moderna could use these positive data to seek approval (accelerated) by the end of 2023. Compared to other brands, Moderna’s flu vaccine exhibited high levels of antibodies in four tested strains.

At the same time, Moderna is reducing its mRNA-based COVID-19 shots as the demand for the vaccine is falling globally.

“We probably overproduced a little bit too much this year, which is why we have excessive unutilized capacity and excessive materials, and that will come down,”

Jamey Mock, CFO Moderna – Reported by Reuters

Source: Moderna, Reuters


Report by: Achuth B S

Published: 14-September-2023

Updated:

Editor's Desk

Next Post

Cobra's Neurotoxic Venom | Details - Types, Effects, and Pharmacology

Fri Sep 15 , 2023
Elapidae is a family of poisonous snakes that includes the cobras. They are recognized for their unusual looks, deadly venom, and the capacity to lift the front portion of their bodies when attacked, generating a distinctive hood shape.
snake venom antibodies

Related Articles